MALAYSIAN BIO-XCELL SDN BHD SEALS A DEAL EXCEEDING US$35M (~RM107M) WITH AGILA BIOTECH SDN BHD DURING BIOPHARMA ASIA 2013

Bangalore, March 19 2013 – In conjunction with Asia’s leading biopharma industry gathering, the BioPharma Asia Convention (BioPharma Asia) held in Singapore from 19th to 21st March 2013 witnessed Malaysian Bio-XCell Sdn Bhd (Bio-XCell) and Agila Biotech Sdn Bhd (Agila Biotech (Malaysia)) sealing a US$34.4m (RM107m) Build-and-Lease Agreement. This agreement is for the establishment of a customized biotech facility located in the Bio-XCell ecosystem in Nusajaya, Johor, Malaysia.

The agreement was signed between En. Rizatuddin Ramli, CEO of Bio-XCell and Dr. Anand Iyer, CEO of Agila Biotech (Malaysia), a subsidiary of India-listed Strides Arcolab Ltd, replacing an earlier agreement signed in May 2011.

“Agila Biotech (Malaysia) is indeed poised to be a major anchor tenant for the Bio-XCell ecosystem and we are extremely pleased to be able to offer our services and support for this promising project,” said En. Rizatuddin Ramli. Bio-XCell will fund RM67.32 million (approximately US$22 Million) to be provided under the Build-and-Lease Agreement with Agila Biotech (Malaysia), which will cover the construction of the building and part of the equipment. All other related state-of-the-art equipment, integration service and testing of this turnkey project (estimated at US$13-15 million) will be funded by Agila Biotech (Malaysia) from internal accruals and funding from external sources.

Work on the facility for the end-to-end manufacturing of biologics located on an 8.77 acre plot is expected to start as soon as all necessary clearances and permits have been obtained and all supplemental agreements have been executed. Both parties are aiming for the R&D and manufacturing facilities to be operational by end 2014.

Agila Biotech (Malaysia) plans to incorporate into its facility at Bio-XCell, the “next-generation” technology platforms which revolutionize the way biomolecules are developed, manufactured and commercialized. It is built around a unique platform that features the innovative application of single-use component technology and transforming biomanufacturing
economics, thus reducing deployment of new manufacturing capacity from 3-5 years to a faster 12-18 months. There's also a significant capital investment savings compared to conventional approaches.

“Successful foray into the biologics space would require building a state-of-the-art infrastructure and strong technical foundation to support three pillars for a successful biotech business,” said Dr. Anand Iyer, while adding that the three pillars are strong pipeline of products; partnering capabilities; and novel formulations/ delivery capabilities, all of which will be found in their new facility planned in Malaysia.

Dr. Iyer also noted that the facility in Bio-XCell represents a strategic move to further bolster Agila Biotech (Malaysia)'s manufacturing presence in the region and tap into unmet global demand and window of opportunity in biologics. The proposed facility at Bio-XCell will include a Mammalian Cell Culture Single-Use Technology Manufacturing Suite, a Microbial Fermentation Single-Use Technology Manufacturing Suite, a Fill & Finish Suite, Analytical/ QC/ R&D labs, utilities infrastructure and offices.

Agila Biotech (Malaysia)'s plans for their facility at Bio-XCell include the development of a state-of-the-art, multi-product, scalable manufacturing facility with a production capacity for mammalian (2KL expandable up to 8KL) and microbial (500 L expandable up to 2KL) products. It also aims to develop advanced formulation/ fill finish facilities to meet Agila Biotech (Malaysia)'s business model which will support the manufacturing of internal pipeline products as well as CMO activities. These facilities will be able to support the production of Recombinant Monoclonal Antibodies (mAbs) from DS to DP, Recombinant Therapeutic Proteins from DS to DP, CMO activities for DS and DP, chemistry and formulation activities for PEGylation, novel formulation development and sterile fill finish facilities for vials, PFS, cartridges and lyophilized products.

Agila Biotech (Malaysia) is also building a 15,000sq.ft, state-of-the-art biologics R&D facility in Bangalore that will support and complement its operations in Malaysia.

Agila Biotech (Malaysia) joins Biocon (India), MetEx (France) and Glycos Biotechnologies (USA) as the early entrants into the Bio-XCell ecosystem. The site is supported by a network of five seaports and two international airports, all within 59km from the park. The ecosystem at Bio-XCell is designed for industrial and healthcare biotechnology with a focus on manufacturing and R&D.

The Bio-XCell and Agila Biotech (Malaysia) partnership is in line with the prestigious BioPharma Asia 2013, which strives to provide more avenues for industry players to converge and collaborate. The annual convention looks to foster similar partnerships by offering a platform for rapport building with industry experts and potential investors. Full details on BioPharma Asia 2013 at [http://www.terrapinn.com/exhibition/biopharma-asia/index.stm](http://www.terrapinn.com/exhibition/biopharma-asia/index.stm)

*Note: US$1 = RM3.11 exchange rate (as at 13th March 2013)*
About Bio-XCell

Bio-XCell, a biotechnology park and ecosystem dedicated to healthcare and industrial biotechnology is being developed by Malaysian Bio-XCell Sdn Bhd, a joint venture company formed between Malaysian Biotechnology Corporation and property developer UEM Land Berhad in 2009.

Bio-XCell is strategically located on 160 acres in Nusajaya, within the Iskandar region of Johor, Malaysia, and close to the border with Singapore providing global connectivity through a network of five seaports and two international airports, all within 59 km. Bio-XCell offers a conducive environment for the development and manufacturing of biologics, pharmaceuticals, bio-based/ green chemicals and other solutions to heal, fuel and green the world.

As a managed park, Bio-XCell will provide its clients and investors with a range of value added benefits including comprehensive infrastructure, high speed internet access, park maintenance and security as well as core facilities to nurture the ecosystem. Key facilities of the park include the Central Hub and Central Utilities Facility (CUF).

The Central Hub is a multipurpose complex featuring a business centre, auditorium, lab & office space as well as amenities such as F&B and retail outlets. The CUF will provide specialised utilities for biomanufacturing to the park’s clients. Clients have options to locate their manufacturing operations at one of the ready-built standard shell buildings or customise their own facility on one of the land plots available at the park.

The park’s global clients include Biocon (India) whose biologics facility will represent the largest insulin production plant in Asia, as well as Agila Biotech (India), METabolic EXplorer (France) and Glycos Biotechnologies (USA).

Bio-XCell aspires to be a catalyst in biotechnology ecosystem in Iskandar Malaysia, with some 3,000 job opportunities expected to be created from its operation in the park. For more details or leasing inquiries, visit: [http://www.bio-xcell.my](http://www.bio-xcell.my)

About Agila Biotech (Malaysia) / Strides Arcolab Limited:

Agila Biotech Sdn Bhd is a wholly owned subsidiary of Agila Biotech Private Limited, India. Agila Biotech (Malaysia) is a Strides Arcolab Limited (Strides) enterprise.

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.
Additional information is available at the company’s website at www.stridesarco.com.

For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>PR Consultancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Anand Iyer, CEO – Agila Biotech  +91 80 6784 0105</td>
<td>Corporate Voice</td>
</tr>
<tr>
<td>Mr. Kannan N: +91 98450 54745 (Investors)</td>
<td>Mahesh Nair, +91 9880376648  <a href="mailto:maheshn@corvoshandwick.co.in">maheshn@corvoshandwick.co.in</a></td>
</tr>
<tr>
<td></td>
<td>Kaveri Mandanna, +91 90089 59697  <a href="mailto:kaveri@corvoshandwick.co.in">kaveri@corvoshandwick.co.in</a></td>
</tr>
</tbody>
</table>